TB-500 10mg

What is TB-500?

TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually all human and animal cells. With a molecular weight of 4,963.50 g/mol, TB-500 represents the active fragment of Thymosin Beta-4 responsible for actin binding, cell migration, and tissue repair. The peptide's amino acid sequence — Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES — encodes the functional regions that drive its regenerative properties.

Thymosin Beta-4 was first isolated from the thymus gland in the 1960s by Dr. Allan Goldstein and has since been identified as one of the most abundant intracellular peptides in mammalian cells. Unlike many signaling peptides, Tβ4 is present at remarkably high concentrations — up to 0.4 mM in some cell types — particularly in platelets, wound fluid, and developing tissues (Goldstein et al., 2012). TB-500 is classified as a regenerative peptide and actin-sequestering protein, positioning it at the intersection of cytoskeletal dynamics and tissue repair biology.

In research settings, TB-500 has garnered significant attention for its multifunctional properties. Studies indicate that the peptide promotes wound healing, reduces inflammation, supports cardiac tissue regeneration, stimulates hair follicle growth, and provides neuroprotective effects. This breadth of activity stems from its fundamental role in regulating actin dynamics — the molecular machinery that underpins cell movement, division, and structural organization. Researchers investigating tissue repair mechanisms frequently include TB-500 alongside BPC-157 in comparative and combination studies due to their complementary mechanisms of action.

Mechanism of Action

The primary molecular mechanism of TB-500 centers on its interaction with globular actin (G-actin), the monomeric form of actin that polymerizes into filamentous actin (F-actin) to form the cell's structural scaffold. TB-500 sequesters G-actin monomers, preventing premature polymerization and maintaining a pool of readily available actin subunits. This process is essential for controlled cytoskeletal remodeling during cell migration, a foundational event in tissue repair (Goldstein et al., 2012).

The actin-binding domain of TB-500 is contained within a central 17-amino acid sequence, LKKTETQ, which directly interacts with G-actin. By regulating the G-actin/F-actin equilibrium, TB-500 enables cells to reorganize their internal scaffolding rapidly — a process critical for cell migration toward sites of injury. Research has demonstrated that even nanomolar concentrations of Tβ4 stimulate keratinocyte migration 2- to 3-fold in Boyden chamber assays (Malinda et al., 1999).

Beyond actin regulation, TB-500 activates several critical signaling cascades. A landmark study published in Nature demonstrated that Tβ4 forms a functional complex with PINCH-1 and integrin-linked kinase (ILK), leading to phosphorylation and activation of Akt (protein kinase B), a key survival kinase. This ILK-Akt pathway promotes cell survival by inhibiting apoptosis and supporting cellular proliferation (Bock-Marquette et al., 2004). The activation of Akt has downstream effects on multiple cellular processes, including glucose metabolism, protein synthesis, and gene transcription.

TB-500 also modulates inflammatory pathways through several mechanisms. Research suggests it downregulates pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 while promoting the expression of anti-inflammatory mediators. The peptide reduces the number of myofibroblasts in wounded tissue, which decreases scar formation and fibrosis (Goldstein et al., 2012). Additionally, Tβ4 promotes angiogenesis — the formation of new blood vessels — by upregulating vascular endothelial growth factor (VEGF) and stimulating endothelial cell migration and tube formation. These converging mechanisms explain why TB-500 research spans such diverse tissue types, from skin and cardiac muscle to neural tissue and connective tissue structures. For researchers studying anti-inflammatory peptides, TB-500 represents a particularly well-characterized candidate.

Research Applications

Wound Healing and Tissue Repair

Wound healing research represents the most extensively studied application of TB-500. The foundational study by Malinda et al. (1999) demonstrated that topical or intraperitoneal administration of Tβ4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days post-wounding in a rat full-thickness wound model. Treated wounds showed significantly increased collagen deposition, angiogenesis, and wound contraction compared to controls. Subsequent research by Philp et al. (2003) extended these findings to impaired healing models, showing that TB-500 accelerated wound repair in both diabetic (db/db) and aged mice. Notably, a synthetic 7-amino acid peptide containing the actin-binding domain (LKKTETQ) replicated the healing effects of the full-length peptide. For deeper analysis of wound healing peptides, see our guide on peptides for wound healing research.

Cardiac Repair and Cardioprotection

TB-500's cardiac research applications are supported by a seminal publication in Nature by Bock-Marquette et al. (2004), which demonstrated that Tβ4 treatment following coronary artery ligation in mice resulted in upregulated ILK and Akt activity, enhanced early myocyte survival, and improved cardiac function. The peptide promoted both myocardial and endothelial cell migration in embryonic hearts and retained these properties in postnatal cardiomyocytes. Further research has shown Tβ4 protects cardiomyocytes from oxidative stress, reduces infarct size, decreases cardiac fibrosis, and promotes neovascularization in ischemic heart tissue. These findings have made TB-500 a leading research candidate in the cardiac regeneration field.

Hair Growth and Follicle Development

TB-500 demonstrates significant hair growth-promoting properties in research models. Philp et al. (2004) reported that Tβ4 stimulated hair growth in normal rats and mice by activating hair follicle stem cells in the bulge region. The peptide increased stem cell migration and differentiation at nanomolar concentrations while upregulating matrix metalloproteinase-2 (MMP-2) expression for extracellular matrix remodeling. Additional work by Philp et al. (2007) confirmed these findings across multiple animal models, including a transgenic Tβ4-overexpressing mouse. These findings suggest significant potential in hair loss research.

Neuroprotection and Brain Injury

Research has demonstrated compelling neuroprotective effects of TB-500 in traumatic brain injury (TBI) models. Xiong et al. (2012) showed that Tβ4 treatment initiated 6 hours post-injury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured hippocampus of rats. Higher doses (30 mg/kg) demonstrated superior benefits compared to lower doses (6 mg/kg), suggesting dose-dependent neuroprotection. These results position TB-500 as a candidate for brain health research.

Anti-Inflammatory and Anti-Fibrotic Effects

TB-500 exhibits robust anti-inflammatory and anti-fibrotic properties across multiple tissue types. Research indicates that the peptide reduces inflammatory cell infiltration, downregulates NF-κB signaling, and decreases production of pro-inflammatory cytokines. In dermal wound models, Tβ4 reduces myofibroblast numbers, resulting in less scar formation and improved tissue architecture (Kleinman & Sosne, 2016). The peptide's anti-fibrotic effects have been observed in cardiac, hepatic, and renal tissue models, broadening its potential research applications in chronic inflammatory and fibrotic conditions. Researchers studying inflammation may also consider KPV and BPC-157 for comparison studies.

Ligament and Connective Tissue Repair

Research by Xia et al. (2013) demonstrated that local administration of Tβ4 enhanced healing of the medial collateral ligament in a rat model, with treated tissues exhibiting uniform fiber bundles, significantly increased collagen fibril diameters, and superior biomechanical properties at 4 weeks post-surgery. These findings extend the tissue repair applications of TB-500 beyond soft tissue wounds into musculoskeletal structures, making it relevant to joint pain research.

Published Research Studies

The scientific literature on Thymosin Beta-4 and its synthetic analog TB-500 is extensive, with hundreds of published studies spanning multiple decades. Below are five key studies that form the foundation of TB-500 research:

1. Malinda et al. (1999) — Journal of Investigative Dermatology
This foundational study (PMID: 10469335) established Tβ4 as a potent wound healing factor. Using a rat full-thickness wound model, researchers demonstrated that Tβ4 applied topically or intraperitoneally increased re-epithelialization by 42–61% over controls. The study also revealed that Tβ4 stimulated keratinocyte migration at concentrations as low as 10 pg in Boyden chamber assays, establishing the extreme potency of this peptide.

2. Bock-Marquette et al. (2004) — Nature
This landmark publication (PMID: 15565145) demonstrated that Tβ4 activates the ILK-Akt survival pathway and promotes cardiac cell migration, survival, and repair. Following coronary artery ligation in mice, Tβ4 treatment resulted in improved cardiac function through enhanced myocyte survival and upregulated ILK and Akt activity. This study established the mechanistic basis for TB-500's cardioprotective effects.

3. Philp et al. (2004) — The FASEB Journal
Published in The FASEB Journal (PMID: 14657002), this study showed that Tβ4 stimulates hair growth by activating hair follicle stem cells in the bulge region. The research demonstrated that Tβ4 promotes migration of clonogenic keratinocytes at nanomolar concentrations and upregulates MMP-2 expression, identifying the mechanism by which the peptide accelerates the active phase of the hair follicle cycle.

4. Xiong et al. (2012) — Journal of Neurosurgery
This controlled study (PMID: 22324420) demonstrated that Tβ4 treatment initiated 6 hours post-TBI reduced cortical lesion volume, decreased hippocampal cell loss, and enhanced neurogenesis in rats. The high-dose group (30 mg/kg IP) showed the greatest improvements in sensorimotor function and spatial learning, with benefits sustained through the 35-day study period.

5. Kleinman & Sosne (2016) — Vitamins and Hormones
This comprehensive review (PMID: 27450738) summarized decades of TB-500 dermal healing research, including Phase 2 clinical trial data showing Tβ4 accelerated repair in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. The review confirmed the peptide's safety profile and its multiple mechanisms of action in tissue repair.

Dosage Protocols in Research

The following dosage information is derived from published research studies and is provided for research reference purposes only. TB-500 is sold exclusively as a research chemical and is not intended for human use.

Published animal studies have utilized a wide range of TB-500 dosing protocols depending on the research model and endpoint being investigated. In the landmark wound healing study by Malinda et al. (1999), Tβ4 was administered topically (5 μg per wound) and intraperitoneally (60 μg per injection) in rats, with both routes demonstrating significant efficacy. In the TBI neuroprotection study by Xiong et al. (2012), rats received intraperitoneal injections of either 6 mg/kg or 30 mg/kg at 6, 24, and 48 hours post-injury, with the higher dose demonstrating superior results.

For cardiac research, Bock-Marquette et al. (2004) administered Tβ4 via intraperitoneal injection at doses calculated to achieve systemic distribution. In the muscular dystrophy model, Spurney et al. (2010) used 150 μg of Tβ4 administered intraperitoneally twice weekly for 6 months (PMID: 20126456). Ligament repair research by Xia et al. (2013) employed local delivery of 1 μg Tβ4 via fibrin sealant directly at the injury site.

For reconstitution, TB-500 is typically dissolved in bacteriostatic water at concentrations suitable for the intended research application. A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a 5 mg/mL solution. For detailed reconstitution guidance, see our how to reconstitute peptides guide. Research protocols commonly employ subcutaneous or intraperitoneal administration, with dosing frequency ranging from daily to twice weekly depending on the experimental design.

Storage and Handling

Proper storage of TB-500 is critical for maintaining peptide integrity and ensuring reproducible research results. In its lyophilized (freeze-dried) form, TB-500 should be stored at -20°C for long-term storage or 2–8°C (refrigerated) for short-term storage of up to several months. The lyophilized powder is highly stable under these conditions, with research-grade preparations maintaining potency for 24 months or more when stored properly.

Once reconstituted with bacteriostatic water, TB-500 solutions should be stored at 2–8°C (refrigerated) and used within 3–4 weeks to ensure optimal stability. Avoid repeated freeze-thaw cycles, as these can degrade the peptide through denaturation and aggregation. When handling reconstituted solutions, use sterile technique and avoid contamination by using fresh, sterile syringes and needles for each withdrawal.

TB-500 is sensitive to extreme heat and prolonged exposure to light. Keep vials protected from direct sunlight and store in a dry environment. For shipment purposes, TB-500 in lyophilized form is stable at ambient temperature for several days but should be refrigerated promptly upon receipt. For comprehensive storage guidance, refer to our article on how to store research peptides.

Safety Profile in Research

Thymosin Beta-4 has demonstrated a favorable safety profile across numerous preclinical and early clinical studies. As a naturally occurring peptide found in high concentrations throughout the human body, Tβ4 is generally well tolerated with minimal adverse effects reported in published research.

In the Phase 2 clinical trials for dermal wound healing reviewed by Kleinman & Sosne (2016), Tβ4 was described as "safe and well tolerated" in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. No significant systemic adverse events were attributed to the peptide treatment. In animal studies, even chronic administration protocols — such as the 6-month dosing regimen in the muscular dystrophy study by Spurney et al. (2010) — did not report significant treatment-related toxicity.

Researchers should note that while Tβ4's pro-angiogenic and cell migration properties are beneficial in tissue repair contexts, these same mechanisms have been investigated for potential roles in tumor biology. Some studies have examined Tβ4 expression levels in various cancer cell lines, though the relationship between exogenous Tβ4 administration and tumor progression remains an active area of investigation. As with all research peptides, thorough review of the current literature is recommended before designing experimental protocols. For a broader overview, consult our research peptide safety guide.

Related Peptides

TB-500 is most frequently compared to BPC-157, another regenerative peptide with tissue repair properties. While both peptides promote healing, they operate through distinct mechanisms: TB-500 primarily regulates actin dynamics and the ILK-Akt survival pathway, whereas BPC-157 acts through nitric oxide (NO) system modulation and growth factor upregulation. Research suggests complementary effects when studied together, which is why the BPC-157 + TB-500 Blend has become a popular research product. For a detailed analysis, see our TB-500 vs BPC-157 comparison.

GHK-Cu is another peptide researched for tissue remodeling and wound healing, though it works primarily through copper-dependent enzymatic pathways and gene expression modulation. Thymosin Alpha-1 shares the thymosin family classification with TB-500 but functions primarily as an immune modulator rather than a tissue repair agent. Researchers interested in peptide stack combinations may consider these related compounds alongside TB-500 in their experimental designs.

Frequently Asked Questions

What is TB-500 used for in research?

TB-500 is primarily used in research studying wound healing, tissue repair, cardiac regeneration, anti-inflammatory responses, hair follicle development, and neuroprotection. As a synthetic analog of Thymosin Beta-4, it enables researchers to investigate actin dynamics, cell migration, and survival signaling pathways across a wide range of tissue types and injury models.

How does TB-500 differ from Thymosin Beta-4?

TB-500 is a synthetic version of Thymosin Beta-4, containing the same 43-amino acid sequence and active regions responsible for actin binding and cell migration. The synthetic form allows for standardized purity and concentration in research settings. Both forms engage the same molecular targets, including G-actin sequestration and ILK-Akt pathway activation.

What is the difference between TB-500 and BPC-157?

TB-500 and BPC-157 are both tissue repair peptides, but they work through different mechanisms. TB-500 regulates actin dynamics and activates the ILK-Akt survival pathway, while BPC-157 modulates nitric oxide systems and upregulates growth factors. Research suggests they may have complementary effects, leading many investigators to study them in combination. See our detailed comparison article for more information.

How should TB-500 be reconstituted for research?

TB-500 is reconstituted by adding bacteriostatic water to the lyophilized powder. For a 10 mg vial, adding 2 mL of bacteriostatic water creates a 5 mg/mL solution. Direct the stream of water against the vial wall rather than directly onto the powder, and gently swirl — never shake — to dissolve. Full reconstitution instructions are available in our reconstitution guide.

What is the molecular weight of TB-500?

TB-500 has a molecular weight of 4,963.50 g/mol. It is a 43-amino acid peptide with the molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S. The peptide is typically supplied as a white lyophilized powder with ≥99% purity as determined by HPLC analysis.

Can TB-500 and BPC-157 be used together in research?

Yes, many research protocols investigate TB-500 and BPC-157 in combination due to their complementary mechanisms of action. TB-500 promotes cell migration through actin regulation while BPC-157 supports angiogenesis and growth factor signaling. Iron Peak Peptides offers a pre-formulated BPC-157 + TB-500 Blend for convenience in research applications.

How long does TB-500 remain stable after reconstitution?

When reconstituted with bacteriostatic water and stored at 2–8°C (refrigerated), TB-500 remains stable for approximately 3–4 weeks. In lyophilized form, it can be stored at -20°C for up to 24 months. Avoid repeated freeze-thaw cycles and protect from light and heat to maximize stability.

Why Buy TB-500 from Iron Peak Peptides?

Iron Peak Peptides is committed to providing researchers with the highest quality TB-500 available. Every batch of our TB-500 10mg undergoes rigorous third-party testing to verify identity, purity, and potency. We guarantee a minimum purity of 99% as confirmed by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis. A quality assurance documentation is available for every batch, providing complete transparency into our quality control process.

Our TB-500 is manufactured in ISO-certified facilities following Good Manufacturing Practice (GMP) guidelines to ensure consistency and reliability across lots. Each vial contains precisely 10 mg of lyophilized TB-500 peptide, verified by quantitative analysis. We ship all peptides with appropriate cold-chain packaging to maintain product integrity during transit. With competitive pricing, fast shipping, and responsive customer support, Iron Peak Peptides is the trusted source for TB-500 and other research peptides. All products are sold strictly for research purposes and are not intended for human consumption.

References

1. Malinda KM, Sidhu GS, Mani H, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-368.
2. Philp D, Badamchian M, Scheremeta B, et al. "Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice." Wound Repair Regen. 2003;11(1):19-24.
3. Philp D, Nguyen M, Scheremeta B, et al. "Thymosin beta4 increases hair growth by activation of hair follicle stem cells." FASEB J. 2004;18(2):385-387.
4. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472.
5. Philp D, Kleinman HK. "Thymosin beta 4 induces hair growth via stem cell migration and differentiation." Ann N Y Acad Sci. 2007;1112:95-103.
6. Spurney CF, Cha HJ, Sali A, et al. "Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse." PLoS One. 2010;5(1):e8976.
7. Goldstein AL, Kleinman HK, Sosne G. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37-51.
8. Xiong Y, Mahmood A, Meng Y, et al. "Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury." J Neurosurg. 2012;116(5):1081-1093.
9. Xia T, Gao R, Zhou G, Liu J, Li J, Shen J. "Thymosin beta4 enhances the healing of medial collateral ligament injury in rat." Regul Pept. 2013;184:1-5.
10. Goldstein AL, Kleinman HK. "Advances in the basic and clinical applications of thymosin β4." Expert Opin Biol Ther. 2015;15 Suppl 1:S139-145.
11. Kleinman HK, Sosne G. "Thymosin β4 Promotes Dermal Healing." Vitam Horm. 2016;102:251-275.